You are viewing AANS Neurosurgeon Volume 27, Number 2, 2018. View our current issue, Volume 28, Number 2, 2019

AANS Neurosurgeon | Volume 27, Number 2, 2018

Advertisement

Gene Identified That May Provide Potential Therapy for Cerebral Cavernous Malformations

Print Friendly, PDF & Email

Researchers at University of California San Diego School of Medicine, with national collaborators, have identified a series of molecular clues to understanding the formation of cerebral cavernous malformations (CCMs). The study offers the first genome-wide analysis of the transcriptome of brain microvascular endothelial cells after KRIT1 inactivation.

“These mouse studies reveal a critical mechanism in the pathogenesis of cerebral cavernous malformations and point to the possibility of using angiogenesis inhibitors, such as TSP1 for potential therapy,” said Mark H. Ginsberg, MD, professor of medicine, UC San Diego School of Medicine.

Click here to read more.

Calendar/Courses

NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis

SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa

2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.

Comments are closed.